Nasdaq OMX Reports In-Line – Analyst Blog
Zacks Market Commentaries (November 6th, 2009) Writes:
Zacks Market Commentaries (November 6th, 2009) Writes:
Zacks Market Commentaries (November 2nd, 2009) Writes:
Dr. Stock Pick (October 20th, 2009) Writes:
Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Tuesday October 20, 2009
DrStockPick.com Stock Report!
BAC, PSFT, PWRM, SO, CSRH, NYX, CVAT, ATVI, AQNM
**************************************************************
BAC, Bank of America Corporation
BAC is one of the world’s largest financial institutions, serving individual consumers, small- and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services.
BAC today announced a strategic alliance with Avjet Corporation, a leading aviation services provider based in Southern California, providing preferred financing terms for clients who finance their aircraft through BAC and take advantage of the business aircraft management services of Avjet.
**************************************************************
PSFT, Powersafe Technology Corp., PSFT.PK
POWERSAFE
...
Zacks Market Commentaries (October 8th, 2009) Writes:
stock-pr (August 7th, 2009) Writes:
CRWENewswire.com is pleased to announce a stock highlight on American International Group, Inc. (AIG), Opexa Therapeutics, Inc. (NASDAQ:OPXA), NYSE Euronext (NYX)
American International Group, Inc. (AIG) today reported its first quarterly profit since the third quarter of 2007, as certain of its businesses stabilized and the company’s results reflected positive valuation changes. AIG also achieved several important milestones in its restructuring program. For the second quarter ended June 30, 2009, AIG reported net income attributable to AIG of $1.8 billion, including net income attributable to AIG common shareholders of $311 million or $2.30 per diluted common share, compared with a net loss of $5.4 billion or $41.13 per diluted share in the second quarter of 2008. Second quarter 2009 adjusted net income was $2.0 billion, compared with an adjusted net loss of $1.3 billion in the second quarter of 2008.
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing a novel T-cell immunotherapy for
...
Zacks Market Commentaries (July 30th, 2009) Writes:
The company swung to a GAAP net loss of $182 million, against net income of $195 million in the year-ago period. The loss was caused by a one-time charge of $442 million related to termination of a contract with LCH.Clearnet and planned job cuts.
Excluding this charge, pro forma earnings per share came in at 51 cents, beating the consensus forecast by more than 13%, or 6 cents.
The transatlantic exchange, which operates across 6 cash equities exchanges in 7 countries and 8 derivatives exchanges, offers trading, clearing and settlement in equities, futures, options, fixed-income and exchange-traded products.
The company stated that net revenues slipped 13.6% year over year to $611 million, which fell short of the consensus estimate by 2%. The decline was attributable to foreign currency fluctuations, price cuts in the U.S. and European markets and sluggish volume in
...